Synta and Roche in potential $1 billion anti-inflammatory deal
This article was originally published in Scrip
Synta Pharmaceuticals could receive up to $1.025 billion from Roche through an anti-inflammatory disease deal. The two firms will discover, develop and commercialise compounds targeting calcium release-activated calcium modulator channels, initially for the treatment of inflammatory diseases. Synta will receive $25 million up front, of which $9 million will be for an initial two-year research period. It is also eligible for a potential additional $1 billion in commercialisation and development milestones for three products, and will receive tiered royalties on product sales. Roche gains worldwide development and commercialisation rights to certain products identified before the end of the research period while Synta retains the rights to co-develop and co-promote the products in indications other than rheumatoid arthritis in the US. Roche launched Actemra (tocilizumab) in Japan last year and hopes to introduce it in the US soon, following an FDA request last September for more information on the drug (Scrip Online, September 9th, 2008). Synta is developing its lead product Elesclomol, an oxidative stress inducer that triggers apoptosis in cancer cells, with GlaxoSmithKline in an agreement worth up to $1 billion.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.